A phase 1b clinical trial (NCT03088176) is currently recruiting participants to study T-VEC in combination with BRAF and MEK inhibitors, dabrafenib and trametinib, for the treatment of advanced BRAF-positive melanoma. The gene discussed is MAP2K7; the disease is melanoma.